Table 5 Association between patient characteristics and immunosuppression using Fisher’s exact test
From: Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma
| Â | Immunosuppression | Â | ||
|---|---|---|---|---|
Characteristics | All (N = 71) | No (N = 61) | Yes (N = 10) | Fisher’s exact test p value |
Gender | ||||
 Female | 31 (44%) | 29 (48%) | 2 (20%) | 0.17 |
 Male | 40 (56%) | 32 (52%) | 8 (80%) |  |
Race | ||||
 Black or African American | 2 (3%) | 2 (3%) | 0 (0%) | > 0.99 |
 White | 69 (97%) | 59 (97%) | 10 (100%) |  |
Age at initial diagnosis, years | ||||
 < =70 | 36 (51%) | 32 (52%) | 4 (40%) | 0.51 |
 > 70 | 35 (49%) | 29 (48%) | 6 (60%) |  |
Initial site | ||||
 Head | 19 (27%) | 14 (23%) | 5 (50%) | 0.39 |
 LE | 15 (21%) | 14 (23%) | 1 (10%) |  |
 Trunk | 23 (32%) | 21 (34%) | 2 (20%) |  |
 UE | 14 (20%) | 12 (20%) | 2 (20%) |  |
AJCC stage at initial diagnosis | ||||
 I | 19 (27%) | 16 (26%) | 3 (30%) | 0.96 |
 II | 10 (14%) | 9 (15%) | 1 (10%) |  |
 III | 30 (42%) | 25 (41%) | 5 (50%) |  |
 IV | 12 (17%) | 11 (18%) | 1 (10%) |  |
Prior chemotherapy or radiation | ||||
 No | 53 (75%) | 46 (75%) | 7 (70%) | 0.71 |
 Yes | 18 (25%) | 15 (25%) | 3 (30%) |  |
UV | ||||
 Negative | 47 (66%) | 45 (74%) | 2 (20%) | < 0.01 |
 Positive | 24 (34%) | 16 (26%) | 8 (80%) |  |
RB1 status | ||||
 Mutant | 32 (45%) | 24 (39%) | 8 (80%) | 0.04 |
 Wild type | 39 (55%) | 37 (61%) | 2 (20%) |  |
TP53 status | ||||
 Mutant | 31 (44%) | 25 (41%) | 6 (60%) | 0.31 |
 Wild type | 40 (56%) | 36 (59%) | 4 (40%) |  |
Virus positive or negative | ||||
 VN | 25 (35%) | 17 (28%) | 8 (80%) | < 0.01 |
 VP | 46 (65%) | 44 (72%) | 2 (20%) |  |